Riskpilot← Back to searchSign inGet full accessVORAX AS
ASActiveOrg 821461642Storgata 1, 1440 DrøbakWholesale of pharmaceutical and medical goods · NACE 4646Est. 20180 employees
Revenue 2024
NOK 0
EBITDA margin
—
+18% vs 2023
Equity ratio
12.7%
Financial strength
Net profit 2024
NOK 2,1M
+311% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -10K | +18% |
| Net profit | NOK 2,1M | +311% |
| Total assets | NOK 8,5M | +7190% |
| Equity | NOK 1,1M | +203% |
| Employees | 0 | — |
Legal name
VORAX AS
Org number
821461642
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
26. september 2018
Share capital
NOK 30 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Eie aksjer/andeler i andre selskap, utøve tjenester i forbindelse med investerings- og handelstransaksjoner, ved egen virksomhet eller ved deltagelse i andre selskaper, også i utlandet.
Address
Storgata 1, 1440 Drøbak
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 0 | −7 | −8 | −12 | −30 | −12 | −10 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −7 | −8 | −12 | −30 | −12 | −10 |
| Net financials | 0 | 0 | 0 | 0 | 0 | −1 000 | 2 146 |
| Profit before tax | 0 | −7 | −8 | −12 | −30 | −1 012 | 2 135 |
| Tax | 0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −7 | −8 | −12 | −30 | −1 012 | 2 135 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 48 | 91 | 83 | 110 | 108 | 117 | 8 527 |
| Equity | 20 | 13 | 5 | −7 | −37 | −1 050 | 1 086 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 28 | 78 | 78 | 117 | 146 | 1 167 | 7 442 |
| Total debt | 28 | 78 | 78 | 117 | 146 | 1 167 | 7 442 |
EBITDA margin
-1010500.0%
This company
15.8%
Market median
-6395670% vs market
20182024
Equity ratio
12.7%
This company
38.2%
Market median
-67% vs market
20182024
Return on equity
196.7%
This company
18.4%
Market median
+969% vs market
20182024
Net profit margin
213548200.0%
This company
8.1%
Market median
+2636397431% vs market
20182024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
6.85×
This company
0.62×
Market median
-1005% vs market
20182024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-08-21 – 2018-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — | |
| Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Svevik As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Svevik As
VORAX AS Board members of VORAX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jarle Dyste Bjelland | Chairman | 0 companies |
| Jarle Bjelland | Chairman | 0 companies |